Boston Scientific (BSX) is under pressure after cautious analyst commentary, including a Wolfe Research downgrade tied to slower Watchman implant sales, along with softer full-year guidance despite Q1 revenue exceeding expectations.

The recent six day slide and softer guidance have pulled Boston Scientific’s share price down 12.7% over the past month and 48.4% year to date, with 1 year total shareholder return down 52.5%. This shows momentum has clearly faded despite solid Q1 revenue and fresh clinical data such as the FRACTURE IDE trial.

If you are reassessing risk after Boston Scientific’s Watchman concerns, it can help to compare with other medtech opportunities harnessing artificial intelligence, starting with 40 healthcare AI stocks

After a 52.5% drop in 1 year total shareholder return and a US$48.85 share price that sits well below consensus targets, the key question is whether Boston Scientific now trades at a discount or whether the market already anticipates slower growth.

Most Popular Narrative: 50.6% Undervalued

Boston Scientific’s most followed narrative pegs fair value at $98.90 per share, which sits well above the last close at $48.85 and frames the current slide in a very different light.

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons:
* Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we have seen in the recent price dips.
* Increased Debt Load: BSX is financing a significant portion of this deal (about $11 billion) with new debt. This has raised concerns about the company’s leverage, with projections hitting 3.3x adjusted EBITDA leverage by the end of 2026.

Want to understand why a deal that pressures earnings and adds leverage still supports a much higher fair value? The narrative leans heavily on stronger profit margins, a richer growth mix and a premium profit multiple that assumes steady expansion in higher growth segments. Curious which assumptions do the heavy lifting in that $98.90 estimate and how they tie back to future earnings power? The full narrative lays out those moving parts in detail.

Result: Fair Value of $98.90 (UNDERVALUED)

However, this upside case could be challenged if Watchman sales remain soft for longer than expected, or if higher leverage from the Penumbra deal weighs on flexibility.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment clearly split between recent setbacks and long term optimism, this is a moment to act quickly and test the data for yourself. To see why some investors still see room for upside, take a closer look at the 4 key rewards.

Looking for more investment ideas?

If Boston Scientific is only one piece of your watchlist, now is the time to widen your search and see what other opportunities the screener brings into focus.

• Target potential upside by scanning for quality stocks that trade below their assessed value using the 47 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies with higher yields and resilient payouts through the 10 dividend fortresses.
• Dial down risk and concentrate on resilient companies that score well on financial stability with the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.